Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine in clinical practice and the issues involved

被引：0
|
作者：
Bradshaw, H. [1 ]
机构：
[1] Singleton Hosp, Swansea, W Glam, Wales
来源：
HIV MEDICINE | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P114
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [31] Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis
    Nunes, Rute
    Bogas, Sarah
    Faria, Maria Joao
    Goncalves, Hugo
    Lucio, Marlene
    Viseu, Teresa
    Sarmento, Bruno
    das Neves, Jose
    JOURNAL OF CONTROLLED RELEASE, 2021, 334 (334) : 453 - 462
  • [32] Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet
    Wang, Xinzhu
    Nutland, Will
    Brady, Michael
    Green, Ian
    Boffito, Marta
    McClure, Myra
    INTERNATIONAL JOURNAL OF STD & AIDS, 2019, 30 (08) : 765 - 768
  • [33] On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know
    Parya Saberi
    Hyman M. Scott
    Journal of General Internal Medicine, 2020, 35 : 1285 - 1288
  • [34] InterPrEP: internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London -analysis of pharmacokinetics, safety and outcomes
    Wang, Xinzhu
    Nwokolo, Nneka
    Korologou-Linden, Roxanna
    Hill, Andrew
    Whitlock, Gary
    Day-Weber, Isaac
    McClure, Myra
    Boffito, Marta
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [35] InterPrEP (II): internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London: analysis of safety and outcomes
    Aloysius, I.
    Zdravkov, J.
    Whitlock, G.
    Alldis, J.
    Nwokolo, N.
    Aylward, A.
    Arvind, A.
    Wang, X.
    Day-Weber, I.
    McClure, M.
    Boffito, M.
    Smith, R.
    Houghton-Price, V.
    Hill, A.
    HIV MEDICINE, 2017, 18 : 25 - 25
  • [36] Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice
    Underhill, Kristen
    Operario, Don
    Skeer, Margie R.
    Mimiaga, Matthew J.
    Mayer, Kenneth H.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (01) : 8 - 13
  • [37] Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results
    Ruane, P. J.
    Clarke, A.
    Post, F. A.
    Schembri, G.
    Jessen, H.
    Trottier, B.
    Bergin, C.
    Molina, J-M
    Wong, P.
    Ebrahimi, R.
    Brainard, D. M.
    Osinusi, A.
    Das, M.
    McCallister, S.
    HIV MEDICINE, 2019, 20 : 95 - 96
  • [38] AT-PrEP, a tool to accompany pre-exposure prophylaxis
    du Mois, Appli
    ACTUALITES PHARMACEUTIQUES, 2019, 58 (584): : 6 - 6
  • [39] Utilizing emergency departments for pre-exposure prophylaxis (PrEP)
    Shull, Jordan A.
    Attys, Julie M.
    Amutah-Onukagha, Ndidiamaka N.
    Hill, Mandy J.
    JOURNAL OF THE AMERICAN COLLEGE OF EMERGENCY PHYSICIANS OPEN, 2020, 1 (06) : 1427 - 1435
  • [40] Pre-exposure HIV prophylaxis (PrEP) background and controversies
    Zalewski, Bartlomiej M.
    Jablonska, Monika
    Mikula, Tomasz
    HIV & AIDS REVIEW, 2009, 8 (04): : 8 - 10
12345